Great news from the US: Uptake of our ranibizumab biosimilar FYB201/Cimerli® in the US has gained momentum from quarter to quarter. Since its launch in October 2022 until the end of 2023, around 190,000 units have been sold. The market share in the ranibizumab market has climbed to 38% by volume. Learn more in today’s press release.